Today: 20 March 2026
Subscribe
Browse Category

Pharmaceutical Industry 16 January 2026 - 2 February 2026

ImmunityBio stock jumps into the weekend as IBRX traders eye an FDA resubmission clock

ImmunityBio stock jumps into the weekend as IBRX traders eye an FDA resubmission clock

ImmunityBio shares (IBRX) closed Friday up 6% at $6.25, bucking broader market declines. The company faces dilution risk after amending a $505 million convertible note with Nant Capital. Attention is on FDA feedback for ANKTIVA’s label expansion in papillary bladder cancer, with a regulatory submission expected within 30 days. The next major event is the late-February ASCO GU conference.
1 February 2026
··
Merck stock jumps to $110 as MRK heads into a big earnings week

Merck stock jumps to $110 as MRK heads into a big earnings week

Merck shares rose 1.8% to $110.27 Friday, outperforming a falling S&P 500 and closing about 2% below their 52-week high. Trading volume topped 19 million shares, well above rivals. Investors await Merck’s Feb. 3 earnings call and new inflation data that could affect rate expectations. Markets reacted to President Trump’s Fed pick and mixed inflation signals.
31 January 2026
···
Denali Therapeutics stock price rises as FDA freezes rival Regenxbio’s Hunter syndrome gene therapy trials

Denali Therapeutics stock price rises as FDA freezes rival Regenxbio’s Hunter syndrome gene therapy trials

Denali Therapeutics shares rose 3.7% to $21.62 Thursday after the FDA halted Regenxbio’s gene therapy trials over a brain tumor case, intensifying focus on Denali’s Hunter syndrome drug under FDA review. Investors await Denali’s clinical data update in early February and a regulatory decision by April 5. The iShares Nasdaq Biotechnology ETF was little changed.
29 January 2026
····
Gilead stock hits fresh 52-week high as Wall Street lifts targets into earnings

Gilead stock hits fresh 52-week high as Wall Street lifts targets into earnings

Gilead Sciences shares rose 1.8% to $140.24 Tuesday afternoon, hitting a 12-month high of $141.69 earlier in the session. Citi, Truist, and BMO raised price targets following upbeat analyst notes and strong momentum for the company’s HIV prevention drug Yeztugo. Investors await early February results and Gilead’s earnings, expected around Feb. 10.
27 January 2026
···
AbbVie stock price edges up: what investors watch ahead of Feb. 4 earnings

AbbVie stock price edges up: what investors watch ahead of Feb. 4 earnings

AbbVie shares rose 0.4% to $220.10 Monday, moving between $217.15 and $221.48 as investors awaited its Feb. 4 earnings report. Health-care stocks held firm, with the sector ETF up 0.4% and Johnson & Johnson and Pfizer also gaining. AbbVie’s upcoming results will highlight its immunology drugs as it faces pressure from declining Humira sales and recent policy deals. Traders are watching Wednesday’s Fed decision before the earnings release.
26 January 2026
···
Gilead stock jumps again as Trodelvy-Keytruda breast cancer data lands in NEJM

Gilead stock jumps again as Trodelvy-Keytruda breast cancer data lands in NEJM

Gilead Sciences shares rose 3.65% to $135.93 after Phase 3 trial results showed Trodelvy plus Keytruda cut the risk of breast cancer progression or death by 35% versus Keytruda and chemotherapy. The company has submitted regulatory filings in the U.S. and Europe. CEO Daniel O’Day plans to sell up to $15.6 million in shares. Investors await Gilead’s earnings report on Feb. 10.
24 January 2026
·
Eli Lilly stock rises after hours as fresh GLP-1 stop data revives a big question ahead of earnings

Eli Lilly stock rises after hours as fresh GLP-1 stop data revives a big question ahead of earnings

Eli Lilly shares rose 0.8% after hours Thursday to $1,087.38. A Reuters report cited nference data showing 36% of patients who stopped Lilly’s weight-loss drug tirzepatide kept weight off after six months, while 28% regained weight. Lilly director Juan R. Luciano acquired 15.286 shares via a deferral plan, per SEC filing. The company reports Q4 earnings February 4.
23 January 2026
···
Johnson & Johnson stock price today: JNJ ends higher, but talc case stays in focus after earnings

Johnson & Johnson stock price today: JNJ ends higher, but talc case stays in focus after earnings

Johnson & Johnson closed up 0.3% at $218.49 Thursday after reporting Q4 revenue of $24.56 billion and adjusted earnings of $2.46 per share. The company projected 2026 sales above estimates but faces ongoing pressure from U.S. drug pricing, tariffs, and talc litigation. A court-appointed special master recommended allowing expert testimony in the New Jersey talc case. J&J plans to appeal.
22 January 2026
···
Johnson & Johnson stock price swings late as JNJ guidance beats views, but talc risk grabs traders again

Johnson & Johnson stock price swings late as JNJ guidance beats views, but talc risk grabs traders again

Johnson & Johnson shares slipped 0.05% to $218.01 in after-hours trading Wednesday after the company projected 2026 sales and profits above Wall Street estimates. Investors weighed the upbeat forecast against renewed legal risks as a court-appointed special master recommended allowing expert testimony in federal talc litigation involving over 67,500 lawsuits. J&J plans to appeal the ruling.
22 January 2026
···
Eli Lilly stock rises as FDA gives ‘Breakthrough’ tag to ovarian cancer drug, earnings date set

Eli Lilly stock rises as FDA gives ‘Breakthrough’ tag to ovarian cancer drug, earnings date set

Eli Lilly shares rose 3.6% to $1,078.52 Wednesday after the FDA granted Breakthrough Therapy designation to its ovarian cancer drug candidate, sofetabart mipitecan. The company will report fourth-quarter earnings on February 4. Director Juan R. Luciano disclosed acquiring about 15 shares through deferred board compensation.
21 January 2026
···
Merck (MRK) stock ends higher on long-term Keytruda cancer-vaccine data; Guardant pact and earnings ahead

Merck (MRK) stock ends higher on long-term Keytruda cancer-vaccine data; Guardant pact and earnings ahead

Merck shares rose 0.6% to $109.45 Tuesday, defying a broad U.S. market selloff. Five-year data showed its personalized melanoma vaccine with Moderna cut recurrence or death risk by 49% in a Phase 2b trial. Investors await Phase 3 trial timing and Merck’s Feb. 3 earnings call for more details. The S&P 500 fell 2.06% and Nasdaq lost 2.39%.
21 January 2026
·····
RAPT Therapeutics stock jumps 64% as GSK agrees $2.2 billion takeover at $58 a share

RAPT Therapeutics stock jumps 64% as GSK agrees $2.2 billion takeover at $58 a share

Rapt Therapeutics shares surged 64% to $57.57 in after-hours trading after GSK agreed to acquire the company for $58 a share in cash, valuing Rapt at about $2.2 billion. The deal centers on ozureprubart, a long-acting anti-IgE antibody. GSK plans to launch a tender offer within 10 business days. Closing depends on a majority of Rapt shares being tendered and U.S. antitrust clearance.
21 January 2026
···
Why ImmunityBio stock jumped nearly 40%: ANKTIVA sales surge and a fresh trial timeline

Why ImmunityBio stock jumped nearly 40%: ANKTIVA sales surge and a fresh trial timeline

ImmunityBio shares soared 40% to $5.52 Friday after the company reported preliminary 2025 net product revenue of $113 million and new approvals for ANKTIVA in Saudi Arabia. Trading volume topped 182 million shares. Enrollment in its key bladder cancer trial is over 85% complete, with FDA submission targeted by late 2026. Early data from its CAR-NK cell therapy showed complete remission in two Waldenström lymphoma patients.
18 January 2026
··
1 2 3 4 … 8

Stock Market Today

  • Kennametal (KMT) Valuation Examined After Recent Share Price Decline
    March 20, 2026, 3:19 AM EDT. Kennametal (KMT) shares fell about 9% last week and 10% over the month following a strong 22% gain in three months. Despite a 67.9% total shareholder return over one year, recent pullbacks raise questions on future growth prospects. The stock trades slightly below analyst targets but well below some intrinsic value estimates, with a fair value around $37.13 versus a $35.18 close. Cost-cutting efforts, including $125 million in expected savings by fiscal 2028, aim to improve margins. However, risks include persistent weak demand and potential delay in realizing efficiencies. Investors should weigh these factors carefully amid mixed market signals and consider alternative industrial exposure opportunities.
Go toTop